225 related articles for article (PubMed ID: 21741090)
1. Review of the therapeutic uses of liraglutide.
Ryan GJ; Foster KT; Jobe LJ
Clin Ther; 2011 Jul; 33(7):793-811. PubMed ID: 21741090
[TBL] [Abstract][Full Text] [Related]
2. Liraglutide: a once-daily incretin mimetic for the treatment of type 2 diabetes mellitus.
Neumiller JJ; Campbell RK
Ann Pharmacother; 2009 Sep; 43(9):1433-44. PubMed ID: 19638470
[TBL] [Abstract][Full Text] [Related]
3. A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus.
Montanya E; Sesti G
Clin Ther; 2009 Nov; 31(11):2472-88. PubMed ID: 20109994
[TBL] [Abstract][Full Text] [Related]
4. Liraglutide for the treatment of type 2 diabetes: a clinical update.
Peters KR
Am J Ther; 2013; 20(2):178-88. PubMed ID: 21734532
[TBL] [Abstract][Full Text] [Related]
5. Liraglutide: once-daily GLP-1 agonist for the treatment of type 2 diabetes.
Ryan GJ; Hardy Y
J Clin Pharm Ther; 2011 Jun; 36(3):260-74. PubMed ID: 21545609
[TBL] [Abstract][Full Text] [Related]
6. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).
Buse JB; Rosenstock J; Sesti G; Schmidt WE; Montanya E; Brett JH; Zychma M; Blonde L;
Lancet; 2009 Jul; 374(9683):39-47. PubMed ID: 19515413
[TBL] [Abstract][Full Text] [Related]
7. GLP-1 receptor agonists and HBA1c target of <7% in type 2 diabetes: meta-analysis of randomized controlled trials.
Esposito K; Mosca C; Brancario C; Chiodini P; Ceriello A; Giugliano D
Curr Med Res Opin; 2011 Aug; 27(8):1519-28. PubMed ID: 21663496
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the efficacy and tolerability profile of liraglutide, a once-daily human GLP-1 analog, in patients with type 2 diabetes ≥65 and <65 years of age: a pooled analysis from phase III studies.
Bode BW; Brett J; Falahati A; Pratley RE
Am J Geriatr Pharmacother; 2011 Dec; 9(6):423-33. PubMed ID: 22055210
[TBL] [Abstract][Full Text] [Related]
9. Effects of liraglutide (NN2211), a long-acting GLP-1 analogue, on glycaemic control and bodyweight in subjects with Type 2 diabetes.
Feinglos MN; Saad MF; Pi-Sunyer FX; An B; Santiago O;
Diabet Med; 2005 Aug; 22(8):1016-23. PubMed ID: 16026367
[TBL] [Abstract][Full Text] [Related]
10. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial.
Garber A; Henry R; Ratner R; Garcia-Hernandez PA; Rodriguez-Pattzi H; Olvera-Alvarez I; Hale PM; Zdravkovic M; Bode B;
Lancet; 2009 Feb; 373(9662):473-81. PubMed ID: 18819705
[TBL] [Abstract][Full Text] [Related]
11. Liraglutide (Victoza) for type 2 diabetes.
Med Lett Drugs Ther; 2010 Apr; 52(1335):25-7. PubMed ID: 20360660
[TBL] [Abstract][Full Text] [Related]
12. Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial.
Madsbad S; Schmitz O; Ranstam J; Jakobsen G; Matthews DR;
Diabetes Care; 2004 Jun; 27(6):1335-42. PubMed ID: 15161785
[TBL] [Abstract][Full Text] [Related]
13. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial.
Russell-Jones D; Vaag A; Schmitz O; Sethi BK; Lalic N; Antic S; Zdravkovic M; Ravn GM; Simó R;
Diabetologia; 2009 Oct; 52(10):2046-55. PubMed ID: 19688338
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis.
Pinelli NR; Hurren KM
Ann Pharmacother; 2011 Jul; 45(7-8):850-60. PubMed ID: 21730278
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of the once-daily human GLP-1 analogue, liraglutide, vs glibenclamide monotherapy in Japanese patients with type 2 diabetes.
Seino Y; Rasmussen MF; Nishida T; Kaku K
Curr Med Res Opin; 2010 May; 26(5):1013-22. PubMed ID: 20199137
[TBL] [Abstract][Full Text] [Related]
16. Albiglutide: a new GLP-1 receptor agonist for the treatment of type 2 diabetes.
Trujillo JM; Nuffer W
Ann Pharmacother; 2014 Nov; 48(11):1494-501. PubMed ID: 25136065
[TBL] [Abstract][Full Text] [Related]
17. Dose-dependent improvement in glycemia with once-daily liraglutide without hypoglycemia or weight gain: A double-blind, randomized, controlled trial in Japanese patients with type 2 diabetes.
Seino Y; Rasmussen MF; Zdravkovic M; Kaku K
Diabetes Res Clin Pract; 2008 Aug; 81(2):161-8. PubMed ID: 18495285
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD).
Zinman B; Gerich J; Buse JB; Lewin A; Schwartz S; Raskin P; Hale PM; Zdravkovic M; Blonde L;
Diabetes Care; 2009 Jul; 32(7):1224-30. PubMed ID: 19289857
[TBL] [Abstract][Full Text] [Related]
19. Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis.
Karagiannis T; Paschos P; Paletas K; Matthews DR; Tsapas A
BMJ; 2012 Mar; 344():e1369. PubMed ID: 22411919
[TBL] [Abstract][Full Text] [Related]
20. Glucose-lowering effects and low risk of hypoglycemia in patients with maturity-onset diabetes of the young when treated with a GLP-1 receptor agonist: a double-blind, randomized, crossover trial.
Østoft SH; Bagger JI; Hansen T; Pedersen O; Faber J; Holst JJ; Knop FK; Vilsbøll T
Diabetes Care; 2014 Jul; 37(7):1797-805. PubMed ID: 24929431
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
